In vitro cytotoxic effect of PARP inhibitor alone and in combination with nab-paclitaxel on triple-negative and luminal A breast cancer cells

Topcul M. R., Cetin I., Turan S. O., Ozar M. O. K.

ONCOLOGY REPORTS, vol.40, pp.527-535, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 40
  • Publication Date: 2018
  • Doi Number: 10.3892/or.2018.6364
  • Journal Name: ONCOLOGY REPORTS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.527-535
  • Keywords: poly(ADP-ribose) polymerase inhibitor, nab-paclitaxel, MCF-7, MDA-MB-231, xCELLigence Real-Time Cell Analysis DP instrument, CHEMOTHERAPY, SUBTYPES, CHEMOSENSITIVITY, MICROTUBULES, GEMCITABINE, FORMULATION, PROGNOSIS, CISPLATIN, TARGETS, ALBUMIN
  • Istanbul University Affiliated: Yes


In the present study, the in vitro cytotoxic effect of poly(ADP-ribose) polymerase (PARP) inhibitor alone and in combination with nab-paclitaxel was evaluated on human triple-negative breast cancer (TNBC) cell line MDA-MB-231 and human luminal A breast cancer cell line MCF-7. For this purpose, cell index (CI) values obtained from xCELLigence Real-Time Cell Analysis (RTCA) DP instrument, mitotic index (MI), labelling index (LI) and apoptotic index (AI) analysis among cell kinetic parameters were used. As a result of PARP inhibitor application, there was a significant decrease in CI, MI and LI and a significant increase in AI for all the experimental groups. After application of PARP inhibitor in combination with nab-paclitaxel, the CI values were decreased for both cell lines, and the differences between the control and all the experimental groups were statistically significant (P<0.01) for all applications. PARP inhibitor, alone or in combination with nab-paclitaxel offers a promising treatment modality in different breast cancer subtypes.